Symposia: Aggressive Lymphomas: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, adult, Biological therapies, clinical trials, Lymphomas, non-Hodgkin lymphoma, Translational Research, elderly, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Combination therapy, health outcomes research, health disparities research, Diseases, real-world evidence, Therapies, aggressive lymphoma, registries, Adverse Events, Lymphoid Malignancies, survivorship, Technology and Procedures, Study Population, Human, machine learning
Type: Oral
Hematology Disease Topics & Pathways:
Research, adult, Biological therapies, clinical trials, Lymphomas, non-Hodgkin lymphoma, Translational Research, elderly, Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Combination therapy, health outcomes research, health disparities research, Diseases, real-world evidence, Therapies, aggressive lymphoma, registries, Adverse Events, Lymphoid Malignancies, survivorship, Technology and Procedures, Study Population, Human, machine learning
Monday, December 12, 2022: 2:45 PM-4:15 PM
La Nouvelle Orleans Ballroom C
(Ernest N. Morial Convention Center)
Moderators:
Victor Manuel Orellana-Noia, MD MSc, Emory University
and
Swetha Kambhampati, MD, City of Hope Comprehensive Cancer Center
Disclosures:
Orellana-Noia: ADC Therapeutics: Consultancy.
This sessions will examine predictors of treatment outcomes in DLBCL, including Richter's transformation and MYC-rearranged DLBCL, and as well as the impact of eligibility criteria on clinical trial enrollment of non-white/non-hispanic participants.
2:45 PM
3:00 PM
3:15 PM
3:30 PM
3:45 PM
4:00 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH